BLUE
Price
$8.41
Change
-$0.56 (-6.24%)
Updated
Dec 18, 04:59 PM (EDT)
68 days until earnings call
NTLA
Price
$12.02
Change
-$1.11 (-8.45%)
Updated
Dec 18 closing price
63 days until earnings call
Ad is loading...

BLUE vs NTLA

Header iconBLUE vs NTLA Comparison
Open Charts BLUE vs NTLABanner chart's image
bluebird bio
Price$8.41
Change-$0.56 (-6.24%)
Volume$1.16K
CapitalizationN/A
Intellia Therapeutics
Price$12.02
Change-$1.11 (-8.45%)
Volume$3.21M
CapitalizationN/A
BLUE vs NTLA Comparison Chart
Loading...
BLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BLUE vs. NTLA commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BLUE is a Hold and NTLA is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (BLUE: $8.41 vs. NTLA: $12.02)
Brand notoriety: BLUE and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BLUE: 186% vs. NTLA: 114%
Market capitalization -- BLUE: $87.21M vs. NTLA: $1.23B
BLUE [@Biotechnology] is valued at $87.21M. NTLA’s [@Biotechnology] market capitalization is $1.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BLUE’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • BLUE’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, BLUE is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BLUE’s TA Score shows that 6 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • BLUE’s TA Score: 6 bullish, 4 bearish.
  • NTLA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BLUE is a better buy in the short-term than NTLA.

Price Growth

BLUE (@Biotechnology) experienced а +7.38% price change this week, while NTLA (@Biotechnology) price change was -14.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.11%. For the same industry, the average monthly price growth was -2.34%, and the average quarterly price growth was +0.25%.

Reported Earning Dates

BLUE is expected to report earnings on Feb 25, 2025.

NTLA is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.23B) has a higher market cap than BLUE($87.2M). NTLA YTD gains are higher at: -60.577 vs. BLUE (-67.500). BLUE has higher annual earnings (EBITDA): -215.81M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. BLUE (3.77M). NTLA has less debt than BLUE: NTLA (102M) vs BLUE (368M). BLUE has higher revenues than NTLA: BLUE (53.1M) vs NTLA (43.1M).
BLUENTLABLUE / NTLA
Capitalization87.2M1.23B7%
EBITDA-215.81M-527.52M41%
Gain YTD-67.500-60.577111%
P/E RatioN/AN/A-
Revenue53.1M43.1M123%
Total Cash3.77M658M1%
Total Debt368M102M361%
FUNDAMENTALS RATINGS
BLUE vs NTLA: Fundamental Ratings
BLUE
NTLA
OUTLOOK RATING
1..100
8366
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
6490
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BLUE's Valuation (21) in the Biotechnology industry is in the same range as NTLA (30). This means that BLUE’s stock grew similarly to NTLA’s over the last 12 months.

BLUE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that BLUE’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as BLUE (99). This means that NTLA’s stock grew similarly to BLUE’s over the last 12 months.

BLUE's Price Growth Rating (64) in the Biotechnology industry is in the same range as NTLA (90). This means that BLUE’s stock grew similarly to NTLA’s over the last 12 months.

BLUE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that BLUE’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BLUENTLA
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 18 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 1 day ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
BLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GEORX6.35N/A
N/A
Pear Tree Essex Environmental Opps R6
MVGMX16.47-0.33
-1.96%
MFS Low Volatility Global Equity R4
CSRYX35.10-0.82
-2.28%
Columbia Select Large Cap Value Inst3
TWGIX60.49-2.12
-3.39%
American Century Growth I
ARYDX12.79-0.48
-3.62%
American Century Global Real Estate R6

BLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, BLUE has been loosely correlated with ARGNF. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BLUE jumps, then ARGNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLUE
1D Price
Change %
BLUE100%
+14.85%
ARGNF - BLUE
44%
Loosely correlated
N/A
NTLA - BLUE
42%
Loosely correlated
-1.87%
COGT - BLUE
41%
Loosely correlated
-0.85%
ARGX - BLUE
41%
Loosely correlated
+0.90%
EDIT - BLUE
40%
Loosely correlated
+2.70%
More